Cellectis S.A. ADR | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR1.4 |
Market Cap |
EUR585.75 M |
Shares Outstanding |
42.41 M |
Public Float |
- |
Cellectis S.A. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
41.61 M |
Public Float |
- |
Cellectis S.A. ADR | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.61 |
Market Cap |
$686.77 M |
Shares Outstanding |
42.45 M |
Public Float |
41.86 M |
Address |
8, rue de la Croix Jarry Paris Ile-de-France 75013 France |
Employees | - |
Website | http://www.cellectis.com |
Updated | 07/08/2019 |
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. |